Jonathan Gill

Jonathan Gill is a High Senior Professor at The University of Texas MD Anderson Cancer Center. His research focuses on oncology, specifically sarcoma, radiation oncology, and tumor biology, with an emphasis on pediatric and adolescent cancers. His latest work identifies CADM1 as an immunotherapeutic target and evaluates novel CADM1-targeting antibody–drug conjugates (ADCs) in preclinical osteosarcoma models, demonstrating dose-response efficacy and payload delivery prediction. He also investigates SMARCB1-deficient renal medullary carcinoma, biomarker-matched therapies in early-phase trials, and sociodemographic impacts on osteosarcoma outcomes. His publications appear in venues such as Cancer Research, Molecular Cancer Therapeutics, and Clinical Cancer Research.